IRO Upclose
Ori Biotech and CTMC Present Scientific Data for New IRO® Platform at ISCT 2024
03. Juni 2024 09:30 ET | Ori Biotech Ltd
Ori Biotech and CTMC announce promising results for IRO, Ori’s newly launched next-generation CGT manufacturing enabling platform.
TIP_link_300x300.jpg
Cell and Gene Therapy Manufacturing Services Market worth $26.72 Billion, Globally, by 2030 – Comprehensive Study by The Insight Partners
27. September 2023 10:12 ET | The Insight Partners
Pune, India, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Cell & gene therapy (CGT) programs are rapidly advancing from research & development to clinical trials and commercial approval. Establishing...
Logo.jpg
Updated Invectys and CTMC announce FDA clearance of IND application for anti-HLA-G CAR-T cell therapy
20. Dezember 2022 08:50 ET | Invectys, Inc.
FDA granted IND clearance for IVS-3001, Invectys’s lead engineered anti-HLA-G CAR-T cell therapy, for the treatment of patients with solid tumors HOUSTON, Texas, Dec. 20, 2022 (GLOBE NEWSWIRE) --...
Logo.jpg
Invectys and CTMC announce FDA clearance of IND application for anti-HLA-G CAR-T cell therapy
19. Dezember 2022 10:24 ET | Invectys, Inc.
FDA granted IND clearance for IVS-3001, Invectys’s lead engineered anti-HLA-G CAR-T cell therapy, for the treatment of patients with solid tumorsHOUSTON, Texas, Dec. 19, 2022 (GLOBE NEWSWIRE) --...
Logo.jpg
INVECTYS, MD ANDERSON AND CTMC ANNOUNCE STRATEGIC COLLABORATION FOR CAR T CELL THERAPY DEVELOPMENT
16. Juni 2022 09:00 ET | Invectys, Inc.
HOUSTON, June 16, 2022 (GLOBE NEWSWIRE) -- Invectys, Inc. (Invectys), The University of Texas MD Anderson Cancer Center and the Cell Therapy Manufacturing Center (CTMC), a joint venture between...